- Ticker
- ABCL
- Price
- 2.68
- Stock movement down
- -0.01 (-0.37%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 788.06M
- Ent value
- 862.10M
- Price/Sales
- 22.02
- Price/Book
- 0.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -47.86%
- 3 year return
- -47.41%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABCL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 22.02 |
| Price to Book | 0.64 |
| EV to Sales | 24.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 294.05M |
| EPS (TTM) | -0.50 |
| FCF per share (TTM) | -0.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 35.79M |
| Gross profit (TTM) | 5.25M |
| Operating income (TTM) | -227.23M |
| Net income (TTM) | -146.90M |
| EPS (TTM) | -0.50 |
| EPS (1y forward) | -0.62 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 14.66% |
| Operating margin (TTM) | -634.92% |
| Profit margin (TTM) | -410.47% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 148.57M |
| Net receivables | 68.78M |
| Total current assets | 813.95M |
| Goodwill | 47.81M |
| Intangible assets | 118.74M |
| Property, plant and equipment | 339.54M |
| Total assets | 1.46B |
| Accounts payable | 26.91M |
| Short/Current long term debt | 73.61M |
| Total current liabilities | 104.88M |
| Total liabilities | 222.60M |
| Shareholder's equity | 1.24B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -41.52M |
| Capital expenditures (TTM) | 86.66M |
| Free cash flow (TTM) | -128.19M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -11.84% |
| Return on Assets | -10.04% |
| Return on Invested Capital | -11.79% |
| Cash Return on Invested Capital | -10.29% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.72 |
| Daily high | 2.74 |
| Daily low | 2.60 |
| Daily Volume | 1.41M |
| All-time high | 53.20 |
| 1y analyst estimate | 15.25 |
| Beta | 0.44 |
| EPS (TTM) | -0.50 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 31 Oct 2024 |
Downside potential
Loading...
Downside potential data
| ABCL | S&P500 | |
| Current price drop from All-time high | -94.96% | -1.02% |
| Highest price drop | -95.51% | -56.47% |
| Date of highest drop | 6 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -76.39% | -11.22% |
| Avg time to new high | 189 days | 12 days |
| Max time to new high | 910 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
788.06M
Marketcap category
Small-cap
Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
586
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page